GemPharmatech Co Ltd
SSE:688046
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
GemPharmatech Co Ltd
Revenue
GemPharmatech Co Ltd
Revenue Peer Comparison
603259
300759
2269
300347
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
G
|
GemPharmatech Co Ltd
SSE:688046
|
Revenue
¥622.2m
|
CAGR 3-Years
33%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Revenue
¥39.4B
|
CAGR 3-Years
29%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Revenue
¥11.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Revenue
¥17B
|
CAGR 3-Years
45%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Revenue
¥7.2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
34%
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Revenue
¥4.2B
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is GemPharmatech Co Ltd's Revenue?
Revenue
622.2m
CNY
Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Revenue amounts to 622.2m CNY.
What is GemPharmatech Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
63%
Over the last year, the Revenue growth was 20%. The average annual Revenue growth rates for GemPharmatech Co Ltd have been 33% over the past three years , 63% over the past five years .
You don't have any saved screeners yet
